Potential application of multi-omics techniques in metabolic dysfunction-associated fatty liver disease： From molecular mechanisms to serological markers
- VernacularTitle:多组学技术在代谢相关脂肪性肝病中的潜在应用： 从分子机制到血清学标志物
- Author:
Zhenni LIU
1
;
Qichen LONG
1
;
Min HU
1
Author Information
- Publication Type:Journal Article
- Keywords: Metabolic Dysfunction-associated Fatty Liver Disease; Biomarkers; Diagnosis
- From: Journal of Clinical Hepatology 2025;41(9):1737-1743
- CountryChina
- Language:Chinese
- Abstract: Metabolic dysfunction-associated fatty liver disease （MAFLD）， formerly known as nonalcoholic fatty liver disease （NAFLD）， has become a common chronic liver disease worldwide. Currently， the clinical methods for diagnosing liver diseases have limitations such as invasive procedures， insufficient sensitivity， and low diagnostic accuracy， posing challenges to the early identification and precise treatment of MAFLD. In recent years， the rapid development of multi-omics techniques has provided new ideas for the precise diagnosis and treatment of MAFLD. Genomics， metabolomics， lipidomics， microbiomics， and proteomics techniques not only offer new insights into the pathogenesis of MAFLD， but also identify novel biomarkers for disease prediction， diagnosis， and staging. Meanwhile， diagnostic models constructed based on multi-omics data have shown good clinical efficacy and laid an important foundation for the development of noninvasive precise diagnostic tools for MAFLD， and therefore， it is expected to realize the transition from traditional diagnosis and treatment to precision medicine. Although the clinical application value of multi-omics markers in the early diagnosis of MAFLD has been recognized to some extent， there are still challenges in clinical translation， such as the standardization of detection， individual heterogeneity， and cost-effectiveness.
